Integra LifeSciences Holdings Corporation

As of June 30, 2026, Integra LifeSciences Holdings Corporation carries a market capitalization of 1.23B, placing it among publicly traded companies globally. Its enterprise value stands at 2.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Integra LifeSciences Holdings Corporation's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Integra LifeSciences Holdings Corporation has 77.78M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.85, and the price-to-book ratio stands at 1.35.

As of June 30, 2026, Integra LifeSciences Holdings Corporation trades at an EV/EBITDA multiple of 14.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 48.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.78B versus a market cap of 1.23B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Integra LifeSciences Holdings Corporation maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 196.37, indicating elevated leverage, while an interest coverage ratio of 2.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Integra LifeSciences Holdings Corporation posted a negative return on equity (ROE) of -0.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.20, reflecting losses generated across the asset base. The company generates approximately 326,345.43 in revenue per employee across its workforce of 4,419.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times Integra LifeSciences Holdings Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Integra LifeSciences Holdings Corporation recorded 6.18M in income tax expense. The company reported a pretax loss of -156,678.70 and -6.34M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Integra LifeSciences Holdings Corporation's stock has declined approximately 21.32% over the past 52 weeks. The 50-day moving average sits at 13.49, while the 200-day moving average is 12.29.

Over the twelve months ended June 30, 2026, Integra LifeSciences Holdings Corporation generated 1.44B in revenue and converted that into -6.34M in net income, yielding earnings per share of -0.08. EBITDA reached 191.75M, while operating income came in at 57.38M.

As of June 30, 2026, Integra LifeSciences Holdings Corporation holds 239.91M in cash and equivalents against 1.79B in total debt, resulting in a net debt position of 1.45B. Total book value stands at 913.27M, with working capital of 753.28M providing operational flexibility.

Integra LifeSciences Holdings Corporation produced 74.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -52.10M in capital expenditures, free cash flow totaled 22.58M - equivalent to 0.29 per share.

Over the twelve months ended June 30, 2026, Integra LifeSciences Holdings Corporation posted a gross margin of 52.47, reflecting its pricing power and cost economics. The operating margin of 3.98 and net profit margin of -0.44 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.84, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.54, meaning Integra LifeSciences Holdings Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Integra LifeSciences Holdings Corporation's most recent stock split took place on January 5, 2017 with a 1:2 split ratio.

As of June 30, 2026, Integra LifeSciences Holdings Corporation has an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.